Effect of Alzheimer disease genetic risk disclosure on dietary supplement use

TitleEffect of Alzheimer disease genetic risk disclosure on dietary supplement use
Publication TypeJournal Article
Year of Publication2010
AuthorsVernarelli, J. A., Roberts, J. S., Hiraki, S., Chen, C. A., Cupples, A. L., & Green, R. C.
JournalThe American journal of clinical nutrition
Volume91
Issue5
Pagination1402-7
Date Published2010 May
ISSN1938-3207
KeywordsAfrican Continental Ancestry Group, Aged, Alzheimer Disease, Apolipoprotein E4, Dietary Supplements, Educational Status, European Continental Ancestry Group, Family, Female, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Random Allocation, Risk Assessment, Risk Factors
Abstract

Genetic susceptibility testing for Alzheimer disease (AD) with APOE genotype disclosure is not recommended for clinical use but is available through direct-to-consumer (DTC) genetic testing companies. Little is known about whether APOE genotype disclosure would actually prompt changes in nutrition behaviors among at-risk individuals.

Alternate JournalAm. J. Clin. Nutr.